Literature DB >> 25820744

Free-hand transperineal targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: single-center experience in China.

Qing Zhang1, Wei Wang, Rong Yang, Gutian Zhang, Bing Zhang, Weiping Li, Haifeng Huang, Hongqian Guo.   

Abstract

OBJECTIVES: To report our experience with free-hand transperineal targeted biopsy with real-time transrectal ultrasound (TRUS) and multiparametric magnetic resonance imaging (mpMRI) fusion images for the diagnosis of prostate cancer (PCa). PATIENTS AND METHODS: A total of 62 consecutive patients suspicious of PCa at the mpMRI scan and PSA >4.0 ng/mL were recruited prospectively. Targeted biopsies (TBs) were carried out for each cancer-suspicious lesion and followed a 12-core systematic biopsy (SB) protocol. Pathological findings of TB and SB were analyzed.
RESULTS: The age of the patients was 68.38 ± 6.57 years (range 51-79 years). The preoperative PSA value was 10.21 ± 5.57 ng/mL (range 4.5-30.1 ng/mL). Preoperative prostate volume was 34.05 ± 9.86 mL (range 19-64 mL). The PCa patients detected by SB and/or TB were 34 (54.8%). Cancer-detected rates of SB and TB cores were 7.53 and 26.2%, respectively (P < 0.001). The positive core length of SB and TB cores was 3.71 ± 2.77 mm (range 1-14 mm) and 5.00 ± 3.04 mm (range 2-17 mm), respectively (P = 0.016). The positive core percent of SB and TB cores was 28.77 ± 20.13% (range 7-100%) and 35.76 ± 18.73 (range 11-100%), respectively (P = 0.048). Moreover, clinically significant PCa cores detected by the SB and TB were 19 cores (2.6%) and 48 cores (18.5%), respectively (P < 0.001).
CONCLUSIONS: Free-hand transperineal TB using real-time TRUS and mpMRI fusion imaging has the ability to improve sampling quality and detect more clinically significant PCa compared with SB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820744     DOI: 10.1007/s11255-015-0957-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

Review 1.  Transperineal biopsy of the prostate--is this the future?

Authors:  Dwayne T S Chang; Benjamin Challacombe; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2013-09-24       Impact factor: 14.432

2.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

3.  Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases.

Authors:  Lona Vyas; Peter Acher; Janette Kinsella; Ben Challacombe; Richard T M Chang; Paul Sturch; Declan Cahill; Ashish Chandra; Richard Popert
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

4.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.

Authors:  Jérémie Haffner; Laurent Lemaitre; Philippe Puech; Georges-Pascal Haber; Xavier Leroy; J Stephen Jones; Arnauld Villers
Journal:  BJU Int       Date:  2011-03-22       Impact factor: 5.588

5.  Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data.

Authors:  Tomoaki Miyagawa; Satoru Ishikawa; Tomokazu Kimura; Takahiro Suetomi; Masakazu Tsutsumi; Toshiyuki Irie; Masanao Kondoh; Tsuyoshi Mitake
Journal:  Int J Urol       Date:  2010-08-27       Impact factor: 3.369

6.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.

Authors:  Thomas Hambrock; Diederik M Somford; Caroline Hoeks; Stefan A W Bouwense; Henkjan Huisman; Derya Yakar; Inge M van Oort; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

7.  Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy.

Authors:  Anurag K Singh; Jochen Kruecker; Sheng Xu; Neil Glossop; Peter Guion; Karen Ullman; Peter L Choyke; Bradford J Wood
Journal:  BJU Int       Date:  2007-12-05       Impact factor: 5.588

8.  Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.

Authors:  Jean-Louis Campos-Fernandes; Laurence Bastien; Nathalie Nicolaiew; Grégoire Robert; Stéphane Terry; Francis Vacherot; Laurent Salomon; Yves Allory; Dimitri Vordos; Andras Hoznek; René Yiou; Jean Jacques Patard; Claude Clément Abbou; Alexandre de la Taille
Journal:  Eur Urol       Date:  2008-06-23       Impact factor: 20.096

Review 9.  The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis.

Authors:  Patricia Harnden; Brian Naylor; Michael D Shelley; Hayley Clements; Bernadette Coles; Malcolm D Mason
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  7 in total

1.  Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.

Authors:  Qing Zhang; Wei Wang; Bing Zhang; Jong Shi; Yao Fu; Danyan Li; Suhan Guo; Shengjie Zhang; Haifeng Huang; Xuping Jiang; Weimin Zhou; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2016-12-22       Impact factor: 2.370

Review 2.  Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.

Authors:  Jianfeng Xu; W Kyle Resurreccion; Zhuqing Shi; Jun Wei; Chi-Hsiung Wang; S Lilly Zheng; Peter J Hulick; Ashley E Ross; Christian P Pavlovich; Brian T Helfand; William B Isaacs
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-28       Impact factor: 5.455

3.  Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy.

Authors:  Haifeng Huang; Wei Wang; Tingsheng Lin; Qing Zhang; Xiaozhi Zhao; Huibo Lian; Hongqian Guo
Journal:  BMC Urol       Date:  2016-11-17       Impact factor: 2.264

4.  Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method.

Authors:  D Thurtle; L Starling; K Leonard; T Stone; V J Gnanapragasam
Journal:  J Clin Urol       Date:  2018-03-05

5.  Magnetic resonance imaging - ultrasound fusion targeted biopsy outperforms standard approaches in detecting prostate cancer: A meta-analysis.

Authors:  Xuping Jiang; Jiayi Zhang; Jingyuan Tang; Zhen Xu; Wei Zhang; Qing Zhang; Hongqian Guo; Weimin Zhou
Journal:  Mol Clin Oncol       Date:  2016-05-20

6.  Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.

Authors:  Qing Zhang; Shiming Zang; Chengwei Zhang; Yao Fu; Xiaoyu Lv; Qinglei Zhang; Yongming Deng; Chuan Zhang; Rui Luo; Xiaozhi Zhao; Wei Wang; Feng Wang; Hongqian Guo
Journal:  J Transl Med       Date:  2017-11-07       Impact factor: 5.531

7.  Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.

Authors:  Huibo Lian; Junlong Zhuang; Wei Wang; Bing Zhang; Jiong Shi; Danyan Li; Yao Fu; Xuping Jiang; Weimin Zhou; Hongqian Guo
Journal:  BMC Urol       Date:  2017-07-05       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.